Condition: Epidermolysis Bullosa · Epidermolysis Bullosa Acquisita · Dystrophic Epidermolysis Bullosa · Sponsor: M. Peter Marinkovich
The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.
This description comes directly from the study's public registry record.
Kunju Clinical Research Coordinator, PhD · 650-721-4902 · kunju@stanford.edu
Always discuss trial participation with your own doctor first.
| Stanford University | Redwood City, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06834035